Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.62 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014861 | 0.94 | KCNA3 (0.64) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL7241377 | 0.92 | LTA4H (0.74) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL3374720 | 0.89 | LTA4H (0.59) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL6560986 | 0.89 | LTA4H (0.59) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL15294291 | 0.89 | LTA4H (0.59) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL29562382 | 0.89 | LTA4H (0.59) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL2844283 | 0.89 | KCNA3 (0.75) | LTA4HKCNA3HTR1BDRD2DRD3 | |
| Water SCHEMBL4967771 | 0.88 | LTA4H (0.57) | LTA4HKCNA3HTR1BCHRNB2CHRNB4 | |
| SCHEMBL2484430 | 0.86 | LTA4H (0.71) | LTA4HKCNA3HTR1BDRD2DRD3 | |
| SCHEMBL2487712 | 0.86 | LTA4H (0.71) | LTA4HKCNA3HTR1BDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62205056-A | — | — | None | — | — | JP | disclosed |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2010048340-A2 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| JP-S62205056-A | LACTIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING SAME | CANON INC | 1987-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, ALG8, ALG1 | LTA4H 876/4885KCNA3 1600/4885HTR1B 4318/4885 |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, DNPEP, ALG8 | LTA4H 1125/4885KCNA3 2290/4885HTR1B 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.